Jaypirca | European Medicines Agency (EMA)

[ad_1]

Overview

Jaypirca is a cancer medicine used to treat adults with mantle cell lymphoma (a cancer of B cells, a type of white blood cell) whose cancer has come back (relapsed) or no longer responds to treatment (refractory), and who had previously received a type of cancer medicine called a Bruton’s tyrosine kinase (BTK) inhibitor.

Mantle cell lymphoma is rare, and Jaypirca was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 21 June 2021. Further information on the orphan designation can be found on the EMA website.

Jaypirca contains the active substance pirtobrutinib.

Jaypirca can only be obtained with a prescription. Treatment should be started and supervised by a doctor experienced in the use of cancer medicines.

The medicine is available as tablets to be taken by mouth once daily. Treatment should be continued until the disease gets worse or the patient gets unacceptable side effects.

For more information about using Jaypirca, see the package leaflet or contact your doctor or pharmacist.

The active substance in Jaypirca, pirtobrutinib, works by blocking an enzyme called BTK, which is important for the growth of B cells, including the abnormal B cells in patients with mantle cell lymphoma. By blocking the action of BTK, the medicine is expected to slow the progression of the disease.

In a main study, Jaypirca was found to reduce the amount of cancer in the body or remove all signs of cancer in patients with MCL whose cancer had come back or did not respond to previous treatments, including with a BTK inhibitor.

The main study involved 164 patients with MCL and the main analysis involved 90 patients who had been treated with a BTK inhibitor before and whose disease could be assessed using a scan. Jaypirca was not compared with another treatment in this study.

Around 57% of patients (51 out of 90) had either a complete or partial response to Jaypirca, which means there was either no sign of the cancer left or the amount of cancer in the body had decreased after treatment. Around 19% had a complete response (17 out of 90). The response to treatment lasted on average 18 months.

For the full list of side effects and restrictions with Jaypirca, see the package leaflet.

The most common side effects with Jaypirca (which may affect more than 1 in 10 people) include tiredness, neutropenia (low levels of neutrophils, a type of white blood cell), diarrhoea and bruising.

The most common serious side effects (which may affect up to 1 in 10 people) include pneumonia (infection of the lungs), neutropenia, anaemia (low levels of red blood cells) and urinary tract infection (infection of the structures that carry urine).

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Jaypirca have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Jaypirca are continuously monitored. Suspected side effects reported with Jaypirca are carefully evaluated and any necessary action taken to protect patients.

Jaypirca received a conditional marketing authorisation valid throughout the EU on 31 October 2023.

English (EN)
(122.82 KB – PDF)

First published: 20/11/2023

View

English (EN)
(938.57 KB – PDF)

First published: 20/11/2023Last updated: 06/02/2025

View

Product information

English (EN)
(579.32 KB – PDF)

First published: 20/11/2023Last updated: 06/02/2025

View

Latest procedure affecting product information:
R/0004

16/08/2024

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

English (EN)
(71.81 KB – PDF)

First published: 20/11/2023

View

Product details

Name of medicine: Jaypirca
Active substance: pirtobrutinib
International non-proprietary name (INN) or common name: pirtobrutinib
Therapeutic area (MeSH): Lymphoma, Mantle-Cell
Anatomical therapeutic chemical (ATC) code: L01

Pharmacotherapeutic group

Antineoplastic agents
Protein kinase inhibitors

Therapeutic indication

Treatment of mantle cell lymphoma (MCL)

[ad_2]

Source link

Subscribe now

To access premium content

BLAST Premier 2022 – Betting Tips and Schedule

Is Overwatch League Getting Outsourced A Good Thing?

The Battle of The Metaverse is Just Getting Started

Vulcan Scholarships, Town Star Nodes, The Sandbox Alpha Event

The Galaxy of Lemuria Review – Play To Earn MMORPG

BLAST Premier 2022 – Betting Tips and Schedule

Zendodo Party Review: Where NFTs Meets DeFi on WAX

Genesis Worlds Metaverse Review – A 100 Years Project

Non-Fungible: A Play-To-Earn Substances Selling Game

Genesis Worlds Interview With CEO Jason Cassidy

Dreamverse NFT Festival: Interview With Twobadour

Inside Axie Infinity With Jihoz – Growth Lead

Alien Worlds Interview With Co-Founder Saro Mckenna

Talking Hash Rush With CMO Alexander Benitez & CM